SCCA Lymphoma Clinical Trials
SGN-35 for CD30-positive Malignancies/Previous SGN-35 study (UW09044)
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
| Status | Conditions | Phase | Study ID |
| Closed | Lymphoma | Phase II |
UW09044 NCT00947856 |
Summary
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with SGN-35 in patients who have previously participated in an SGN-35 study.
|
|
Eligibility Criteria (must meet the following to participate in this study)
| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Participated in a previous SGN-35 study.
- CD30-positive hematologic malignancy.
- At a minimum, experienced clinical benefit in the prior SGN-35 study.
Exclusion Criteria:
Withdrew consent to participate in any prior SGN-35 study.
Last Updated
September 14, 2012See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
Join Us On